Introduction:
Danish CDMO 21st.BIO A/S has opened a new pilot plant facility in Copenhagen to accelerate scaling of biotech processes in various industries. The facility aims to bridge the gap between laboratory scale and industrial production of novel food and pharmaceutical proteins and peptides.
- The new pilot plant facility will help biotech companies reach industrial scale faster and more cost-effectively.
- It will provide contract services worldwide, ranging from strain design to upscaling industrial production of proteins and peptides.
- The facility can help define parameters and equipment for large-scale production of proteins by fermentation.
- Denmark, known for its expertise in bioproduction, has the opportunity to contribute its technology and expertise to the global market.
- EU Executive Vice-President Margrete Vestager emphasized the potential of the biotech sector and called for collaboration between policy makers and industry stakeholders.
Conclusion:
The opening of the pilot plant facility by 21st.BIO A/S in Denmark marks a significant milestone in the biotech industry. It offers biotech companies the resources and support they need to scale up their processes and brings Denmark closer to achieving its goal of becoming a leader in bioproduction. With the potential for organic production to contribute significantly to the global economy, the demand for bioproduction technology is expected to rise in the coming years. The facility’s focus on proteins and peptides for various applications highlights the importance of these biomolecules in industries such as nutrition, food and beverage, agriculture, biomaterials, and biopharma.
